Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

108.80
-1.0500-0.96%
Post-market: 108.72-0.0800-0.07%19:53 EDT
Volume:4.28M
Turnover:466.02M
Market Cap:135.34B
PE:23.00
High:110.15
Open:109.21
Low:108.16
Close:109.85
Loading ...

Gilead: Intend to Investigate and Pursue Potential of Both Agents and Work With Regulatory Authorities to Resolve Issues

THOMSON REUTERS
·
10 Jun

RBC Capital Remains a Hold on Gilead Sciences (GILD)

TIPRANKS
·
10 Jun

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
06 Jun

A New Shot Prevents HIV and Breathes New Life Into a Stagnant Biotech -- Heard on the Street -- WSJ

Dow Jones
·
05 Jun

Gilead Sciences’ Oncology Advancements: Trodelvy’s Potential to Boost Stock Value

TIPRANKS
·
05 Jun

Daniel Patrick O'Day, Chairman & CEO, Reports Disposal of Common Shares in Gilead Sciences Inc

Reuters
·
03 Jun

Gilead Sciences Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
03 Jun

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-06-02

Reuters
·
02 Jun

Gilead Sciences (GILD) Gets a Hold from Truist Financial

TIPRANKS
·
02 Jun

Merck, Gilead Combination Reduces Disease-Progression Risk of Breast Cancer in Phase 3 Study

MT Newswires Live
·
02 Jun

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD)

TIPRANKS
·
02 Jun

Gilead’s Kite announces real-world safety, effectiveness of Yescarta

TIPRANKS
·
02 Jun

Gilead announces data on Trodelvy plus Keytruda

TIPRANKS
·
02 Jun

Gilead Sciences Reveals Promising Results of Yescarta® in Outpatient Care for Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

Reuters
·
01 Jun

Gilead's CAR-T cell therapy shows promise in deadly brain cancer

Reuters
·
01 Jun

Gilead Sciences Unveils Promising Phase 3 Results: Trodelvy Plus Keytruda Reduces Disease Progression Risk by 35% in Metastatic Triple-Negative Breast Cancer

Reuters
·
31 May

Keytruda® (Pembrolizumab) Plus Trodelvy® (Sacituzumab Govitecan-Hziy) Reduced Risk of Disease Progression or Death by 35% Versus Keytruda Plus Chemotherapy in First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer (Tnbc)

THOMSON REUTERS
·
31 May

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
30 May

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-05-29

Reuters
·
29 May

Gilead Sciences Inc. Stock Rises Tuesday, Still Underperforms Market

Dow Jones
·
28 May